Bonesupport

STRONG UNDERLYING BUSINESS MOMENTUM

OCTOBER – DECEMBER 2023

• Net sales increased by 67 percent (60 percent at constant exchange rates) and amounted to SEK 172.7 million (103.2).
• The North America (NA) segment reported a sales growth of 79 percent (71 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 38 percent (32 percent at constant exchange rates).
• The gross margin amounted to 91.8 percent (91.5).
• The operating result before effects from the Group’s incentive programs amounted to SEK +11.2 million (-10.1). Reported operating result amounted to SEK -7.7 million (-19.3).
• Earnings per share before and after dilution were SEK +0.16 (-0.32).
• Adjusted for deferred tax income on tax losses carried forward and other temporary differences, the earnings per share before and after dilution were SEK -0.16.

JANUARY – DECEMBER 2023

• Net sales increased by 80 percent (72 percent at constant exchange rates) and amounted to SEK 591.1 million (328.8).
• The North America (NA) segment reported a sales growth of 104 percent (95 percent at constant exchange rate).
• The Europe & Rest of the World (EUROW) segment reported a sales growth of 33 percent (28 percent at constant exchange rates).
• The gross margin amounted to 91.5 percent (90.5)
• The operating result before effects from the Group’s incentive programs amounted to SEK +54.1 million (-36.2). Reported operating result amounted to SEK +13.9 million (-64.5).
• Earnings per share before dilution were SEK +3.77 (-1.06).
• Earnings per share after dilution were SEK +3.74 (-1.06).
• Adjusted for deferred tax income on tax losses carried forward and other temporary differences, which have been reported for the first time this year, the earnings per share before and after dilution were SEK +0.10.

"Continued success for CERAMENT G in the US." Emil Billbäck, CEO

EVENTS DURING THE REPORTING PERIOD

• In October, CERAMENT V was awarded Breakthrough device designation for the indication bone infection by the US Food and Drug Administration (FDA).
• In November, The US Centers for Medicare & Medicaid Services (CMS) granted the Transitional Pass-Through Payment (TPT) for CERAMENT G.
• In connection with a Capital Markets Day in November, the Company announced an updated outlook for 2024 with sales growth of over 40 percent (in constant currency). Furthermore, the Company's plans were presented, including future extension into spinal fusion and a planned market application for CERAMENT V in the US in the first quarter of 2025.
• In December, the Company received MDR certificates for CERAMENT BVF and CERAMENT V.

EVENTS AFTER THE REPORTING PERIOD

• Decision to submit application, in Q1 2024, to FDA for CERAMENT BVF on Spine Interbody Fusion based on existing available bone remodeling data (previously communicated timing was Q4 2024).